Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trial

Autores da FMUP
Participantes de fora da FMUP
- Cleland, JGF
- Girerd, N
- Pellicori, P
- Hazebroek, MR
- Verdonschot, J
- Collier, TJ
- Petutschnigg, J
- Clark, AL
- Staessen, JA
- Heymans, S
- Zannad, F
- Rossignol, P
Unidades de investigação
Abstract
[No abstract available]
Dados da publicação
- ISSN/ISSNe:
- 1861-0692, 1861-0684
- Tipo:
- Letter
- Páginas:
- 330-332
- PubMed:
- 36279002
- Link para outro recurso:
- www.scopus.com
Clinical Research in Cardiology D. Steinkopff-Verlag
Citações Recebidas na Web of Science: 2
Citações Recebidas na Scopus: 5
Documentos
- Não há documentos
Filiações
Keywords
- Heart Failure; Humans; Kidney; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; Treatment Outcome; brain natriuretic peptide; hepatitis A virus cellular receptor 1; loop diuretic agent; natriuretic factor; potassium; renin; spironolactone; mineralocorticoid antagonist; spironolactone; atrial fibrillation; blood pressure; clinical trial (topic); collagen synthesis; controlled study; coronary artery disease; diabetes mellitus; ECG abnormality; estimated glomerular filtration rate; heart failure; heart function; heart left ventricle ejection fraction; human; hypertension; kidney function; Letter; microalbuminuria; randomized controlled trial (topic); risk factor; systolic blood pressure; heart failure; heart stroke volume; kidney; physiology; treatment outcome
Financiamento
Projetos associados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022